Only in Titles

           Search results for: Recombinant Human BID Proteins    

paperclip

#28455246   2017/04/29 Save this To Up

Fn14·TRAIL fusion protein is oligomerized by TWEAK into a superefficient TRAIL analog.

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) demonstrates specific anti-cancer activity, but insufficient efficacy in patients. A fusion protein Fn14·TRAIL, that combines soluble TRAIL molecule with a specific TWEAK receptor Fn14, is a better apoptosis-inducer for hepatocellular carcinomas than soluble TRAIL. However, Fn14·TRAIL does not effectively induce apoptosis in tumors of the lymphoid origin. As malignant cell apoptosis is strongly enhanced by secondary oligomerization of TRAIL, we tested the hypothesis that soluble Fn14·TRAIL can be oligomerized and become more active by adding TWEAK, a cytokine secreted in the tumor environment. We revealed that TWEAK and Fn14·TRAIL spontaneously formed a stable complex that induced apoptosis of malignant lymphoblasts earlier and more efficiently than TRAIL. The TWEAK-modified Fn14·TRAIL oligomer bound to target cells and delivered apoptotic signaling via TRAIL receptors. The oligomer induced faster and stronger cleavage of procaspase-8, -9, and -3; BID; poly-ADP ribose polymerase; and RIP compared to TRAIL. The oligomer also reduced expression of the anti-apoptotic proteins c-FLIP short and cIAP-1. Our data indicate that Fn14·TRAIL can be converted into a highly effective TRAIL oligomer upon binding to TWEAK.

1171 related Products with: Fn14·TRAIL fusion protein is oligomerized by TWEAK into a superefficient TRAIL analog.

Recombinant Human TRAIL ( Recombinant Human TRAIL ( Recombinant Human TRAIL ( Recombinant Human TRAIL A SEC13 protein isoform 1 a cell cycle progression 2 steroidogenic acute regul amyloid beta precursor pr Recombinant Human c-jun A Recombinant Human c-jun A Recombinant Human c-jun A Recombinant Human TRAIL P

Related Pathways

paperclip

#27878291   2016/11/23 Save this To Up

Adenovirus-mediated truncated Bid overexpression induced by the Cre/LoxP system promotes the cell apoptosis of CD133+ ovarian cancer stem cells.

Cancer stem cells are a small subset of cancer cells that contribute to cancer progression, metastasis, chemoresistance and recurrence. CD133-positive (CD133+) ovarian cancer cells have been identified as ovarian cancer stem cells. Adenovirus-mediated gene therapy is an innovative therapeutic method for cancer treatment. In the present study, we aimed to develop a new gene therapy to specifically eliminate CD133+ ovarian cancer stem cells by targeting CD133. We used the Cre/LoxP system to augment the selective expression of the truncated Bid (tBid) gene as suicide gene therapy in CD133+ ovarian cancer stem cells. The adenovirus (Ad)-CD133-Cre expressing Cre recombinase under the control of the CD133 promoter and Ad-CMV-LoxP-Neo-LoxP-tBid expressing tBid under the control of the CMV promoter were successfully constructed using the Cre/LoxP switching system. The co-infection of Ad-CMV-LoxP-Neo-LoxP-tBid and Ad-CD133-Cre selectively induced tBid overexpression, which inhibited cell growth and triggered the cell apoptosis of CD133+ ovarian cancer stem cells. The Cre/LoxP system-mediated tBid overexpression activated the pro-apoptotic signaling pathway and augmented the cytotoxic effect of cisplatin in CD133+ ovarian cancer stem cells. Furthermore, in xenograft experiments, co-infection with the two recombinant adenoviruses markedly suppressed tumor growth in vivo and promoted cell apoptosis in tumor tissues. Taken together, the present study provides evidence that the adenovirus-mediated tBid overexpression induced by the Cre/LoxP system can effectively eliminate CD133+ ovarian cancer stem cells, representing a novel therapeutic strategy for the treatment of ovarian cancer.

1954 related Products with: Adenovirus-mediated truncated Bid overexpression induced by the Cre/LoxP system promotes the cell apoptosis of CD133+ ovarian cancer stem cells.

Tissue array of ovarian g Macrophage Colony Stimula Macrophage Colony Stimula Human Ovarian Microvascul Dog Receptor-binding canc Stemez hN2 Human Neuron D Multiple organ cancer tis 129 Mouse Embryonic Stem Rat Mesenchymal Stem Cell CA125, Ovarian Cancer An CA125, Ovarian Cancer An CA125, Ovarian Cancer An

Related Pathways

paperclip

#27540883   2016/08/19 Save this To Up

EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM.

The aim of this post hoc analysis was to assess the efficacy and safety of once-weekly dulaglutide in Hispanic/Latino patients with type 2 diabetes (T2D) in phase 3 AWARD trials 1 to 6.

1710 related Products with: EFFICACY AND SAFETY OF DULAGLUTIDE IN HISPANIC/LATINO PATIENTS WITH TYPE 2 DIABETES IN THE AWARD CLINICAL PROGRAM.

Multiple cancer (12 type) Multi organ carcinoma tis Multi organ carcinoma tis Liver carcinoma and norma Lung carcinoma and normal Colon cancer and normal t Prostate cancer, adjacent Bladder cancer tissue arr Bladder cancer tissue arr Human normal bone and ost Breast cancer tissue arra Breast tumor survey tissu

Related Pathways

paperclip

#27488824   2016/09/30 Save this To Up

Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers.

Approximately 90% of T2D patients in the US are diagnosed and treated in the primary care setting, and the majority of the burden of disease management falls to primary care providers. Here, we discuss the clinical data for once weekly dulaglutide, e.g. the results of seven completed Phase 3 trials, patient preference studies, patient reported outcomes (PRO), and clinical data surrounding the dulaglutide administration device. Dulaglutide 1.5 mg once weekly demonstrated superiority to placebo, metformin, sitagliptin, exenatide BID, and insulin glargine (in 2 trials), and non-inferiority to liraglutide in reduction of HbA1c from baseline, with an acceptable safety profile. Dulaglutide-treated patients achieved the composite endpoint of an HbA1c <7.0% with no hypoglycemia, no severe hypoglycemia, and no weight gain significantly more than metformin, sitagliptin, exenatide BID or insulin glargine treated patients. Dulaglutide consistently showed an early onset of glycemic control, lasting up to 104 weeks. Additionally, PRO and patient preference data support the benefit of once weekly dulaglutide for the treatment of T2D.

2782 related Products with: Dulaglutide in the treatment of adult type 2 diabetes: a perspective for primary care providers.

High density (188 cases 2 High density (188 cases 2 Breast invasive ductal ca PERMANENT AQUEOUS MOUNTIN Multiple lung carcinoma ( High density (208 cores), Multiple cancer (12 type) MOUSE ANTI CANINE DISTEMP MOUSE ANTI HUMAN CD15, Pr MOUSE ANTI HUMAN CD15, Pr Top 4 types of cancer (co Primary Antibody Diluent

Related Pathways

paperclip

#27473824   2016/09/09 Save this To Up

Dual targeting and enhanced cytotoxicity to HER2-overexpressing tumors by immunoapoptotin-armored mesenchymal stem cells.

Mesenchymal stem cells (MSCs) are promising vehicles for the delivery of anticancer agents in cancer therapy. However, the tumor targeting of loaded therapeutics is essential. Here, we explored a dual-targeting strategy to incorporate tumor-tropic MSC delivery with HER2-specific killing by the immunoapoptotin e23sFv-Fdt-tBid generated in our previous studies. The MSC engineering allowed simultaneous immunoapoptotin secretion and bioluminescence detection of the modified MSCs. Systemic administration of the immunoapoptotin-engineered MSCs was investigated in human HER2-reconstituted syngeneic mouse models of orthotopic and metastatic breast cancer, as well as in a xenograft nude mouse model of orthotopic gastric cancer. In vivo dual tumor targeting was confirmed by local accumulation of the bioluminescence-imaged MSCs and persistence of His-immunostained immunoapoptotins in tumor sites. The added tumor preference of MSC-secreted immunoapoptotins resulted in a significantly stronger antitumor effect compared with purified immunoapoptotins and Jurkat-delivered immunoapoptotins. This immunoapoptotin-armored MSC strategy provides a rationale for its use in extended malignancies by combining MSC mobility with redirected immunoapoptotins against a given tumor antigen.

1574 related Products with: Dual targeting and enhanced cytotoxicity to HER2-overexpressing tumors by immunoapoptotin-armored mesenchymal stem cells.

Rat Mesenchymal Stem Cell Macrophage Colony Stimula Macrophage Colony Stimula Rat Mesenchymal Cells Rat Mesenchymal Stem Cell Mesenchymal Stem Cell Adi Mesenchymal Stem Cell Ost Human Tonsil Microvascula Stemez hN2 Human Neuron D AccuzolTM Total RNA Extra Lysosome Cytotoxicity Dua 129 Mouse Embryonic Stem

Related Pathways

paperclip

#27294920   2016/06/14 Save this To Up

Studies to Prevent Degradation of Recombinant Fc-Fusion Protein Expressed in Mammalian Cell Line and Protein Characterization.

Clipping of recombinant proteins is a major issue in animal cell cultures. A recombinant Fc-fusion protein, VEGFR1(D1-D3)-Fc expressed in CHOK1SV GS-KO cells was observed to be undergoing clippings in lab scale cultures. Partial cleaving of expressed protein initiated early on in cell culture and was observed to increase over time in culture and also on storage. In this study, a few parameters were explored in a bid to inhibit clipping in the fusion protein The effects of culture temperature, duration of culture, the addition of an anti-clumping agent, ferric citrate and use of protease inhibitor cocktail on inhibition of proteolysis of the Fc fusion were studied. Lowering of culture temperature from 37 to 30 °C alone appears to be the best solution for reducing protein degradation from the quality, cost and regulatory points of view. The obtained Fc protein was characterized and found to be in its stable folded state, exhibiting a high affinity for its ligand and also biological and functional activities.

2028 related Products with: Studies to Prevent Degradation of Recombinant Fc-Fusion Protein Expressed in Mammalian Cell Line and Protein Characterization.

Recombinant Human IFN-alp Recombinant Human IFN-alp Toxoplasma gondii GRA8, r FIV Core Ag, recombinant Bone Morphogenetic Protei Recombinant Influenza HA Recombinant Influenza HA Recombinant Influenza HA Recombinant Human c-jun A Recombinant Human c-jun A Recombinant Human c-jun A Recombinant EBV p18 [GST-

Related Pathways

paperclip

#27152961   2016/05/07 Save this To Up

Asp-ase Activity of the Opossum Granzyme B Supports the Role of Granzyme B as Part of Anti-Viral Immunity Already during Early Mammalian Evolution.

Granzyme B is one of the key effector molecules in our defense against viruses and intracellular bacteria. This serine protease together with the pore forming protein perforin, induces caspase or Bid-dependent apoptosis in target cells. Here we present the first characterization of a granzyme B homolog, the grathepsodenase, in a non-placental mammal, the American opossum (Monodelphis domestica). The recombinant enzyme was produced in a human cell line and used to study its primary and extended cleavage specificity using a panel of chromogenic substrates and recombinant protein substrates. The opossum granzyme B was found to have a specificity similar to human granzyme B, although slightly less restrictive in its extended specificity. The identification of a granzyme B homolog with asp-ase (cleaving after aspartic acid) specificity in a non-placental mammal provides strong indications that caspase or Bid-dependent apoptosis by a serine protease with a conserved primary specificity has been part of anti-viral immunity since early mammalian evolution. This finding also indicates that an asp-ase together with a chymase were the first two serine protease genes to appear in the mammalian chymase locus.

2103 related Products with: Asp-ase Activity of the Opossum Granzyme B Supports the Role of Granzyme B as Part of Anti-Viral Immunity Already during Early Mammalian Evolution.

Anti beta3 AR Human, Poly Rabbit Anti-Granzyme K Po Mouse Anti-Human Granzyme Mouse Anti-Bacteroides th Anti-BACE-1 (Memapsin-2, Anti-BACE-1 (Memapsin-2, Anti VGLUT 1 Rat, polyclo MOUSE ANTI BOVINE ROTAVIR Anti Rat VGLUT 2, Rabbit Viral antibodies, anti-R BACTERIOLOGY BACTEROIDES Mouse anti-bovine type I

Related Pathways

paperclip

#26886127   2016/04/03 Save this To Up

Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis.

Effective and safe antiviral treatment regimens are needed for patients with chronic hepatitis C (CHC) and cirrhosis.

1454 related Products with: Ritonavir-boosted danoprevir-based regimens in treatment-naive and prior null responders with HCV genotype 1 or 4 and compensated cirrhosis.

Androstadienone C19H26O C ∆1-Androstene-3β,17β- Androst-4-ene-3,17-dion-1 Epiandrosterone (3 beta H HCV core 2 119aa recombin HCV NS3 1192 1456aa recom HCV NS3 1359 1456aa antig HCV NS4 mosaic recombinan HCV NS5 2212 2313aa recom Goat Anti- PSCA (aa27-40) Goat Anti-Human ORAI1 CRA Goat Anti-Rat Connexin 43

Related Pathways

  •  
  • No related Items
paperclip

#26867770   2016/08/26 Save this To Up

Enzymatically active cathepsin D sensitizes breast carcinoma cells to TRAIL.

Cathepsin D (CD), a ubiquitously expressed lysosomal aspartic protease, is upregulated in human breast carcinoma and many other tumor types. CD has been repeatedly reported to act as key mediator of apoptosis induced by various chemotherapeutics. However, there is still controversy over the role of enzymatic/proteolytic versus protein-protein interaction activities of CD in apoptotic signaling. The elucidation of molecular mechanism responsible for the effect of CD in the chemotherapy-induced cell death is crucial for development of an appropriate strategy to target this protease in cancer treatment. Therefore, the objective of this study was to investigate the molecular mechanism behind the CD-mediated regulation of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced cell death. For this purpose, MDA-MB-231 breast carcinoma cells with an increased level of wt CD (CD) or mutant enzymatically inactive CD (ΔCD) were subjected to TRAIL and the frequency of apoptosis was determined. Our results show that CD facilitates the TRAIL-induced apoptosis of MDA-MB-231 breast cancer cells in enzymatic activity-dependent manner. Moreover, the importance of endosomal/lysosomal acidification in this process was documented. Analysis of the potential substrates specifically cleaved by CD during the TRAIL-induced apoptosis confirmed caspase-8 and Bid proteins as the CD targets. Moreover, in search for protein regulators of apoptosis that can be cleaved by CD at physiologically relevant pH, we identified the Bcl-2 protein as a suitable candidate. The modulatory role of CD in cell response to TRAIL was also confirmed in another breast cancer cell line SKBR3. These experiments identified the CD enzymatic activity as a new factor affecting sensitivity of breast cancer cells to TRAIL.

2541 related Products with: Enzymatically active cathepsin D sensitizes breast carcinoma cells to TRAIL.

Epidermal Growth Factor ( Epidermal Growth Factor ( Recombinant Viral antige Allergens, Dermatophagoid Breast invasive ductal ca Breast invasive ductal ca High density breast invas High density (188 cases 2 High density (188 cases 2 Breast invasive ductal ca Breast invasive ductal ca Breast invasive ductal ca

Related Pathways

paperclip

#26640956   2015/12/08 Save this To Up

Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.

Nitazoxanide (NTZ) plus pegylated interferon and ribavirin (Peg-IFN/RBV) improved the sustained virological response (SVR) achieved with Peg-IFN/RBV in hepatitis C virus genotype 4 (HCV-4)-monoinfected patients. There are no data currently on the efficacy of Peg-IFN/RBV plus NTZ for human immunodeficiency virus (HIV)/HCV-4 coinfection. Therefore, the objectives of this clinical trial were to assess the efficacy and to evaluate the safety of Peg-IFN/RBV plus NTZ in HIV/HCV-4-coinfected patients.

1454 related Products with: Low Efficacy of Pegylated Interferon plus Ribavirin plus Nitazoxanide for HCV Genotype 4 and HIV Coinfection.

HIVCN54gag (256 458 n.t.) HIVCN54gag (432 574 n.t.) HCV core 2 119aa recombin HCV NS3 1192 1456aa recom HCV NS3 1359 1456aa antig HCV NS4 mosaic recombinan HCV NS5 2212 2313aa recom Recombinant HCV Genotype- Recombinant HCV Genotype- Recombinant HCV Genotype- Recombinant HCV Genotype- Recombinant HCV Genotype-

Related Pathways